High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity by Yang, Runkuan et al.
 
 
 
This document has been downloaded from  
Tampub – The Institutional Repository of University of Tampere 
 
 
410.5Kb  
View/Open  
Author(s):  Yang, Runkuan; Zhang, Shutian; Cotoia, Antonella; Oksala, Niku; Zhu, Shengtao; Tenhunen, Jyrki 
Title:  High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity 
Year:  2012 
Journal Title:  BMC Gastroenterology 
Vol and 
number:  12 : 45  
Pages:  1-8 
ISSN:  1471-230X 
Discipline:  Surgery, anesthesiology, intensive care, radiology 
School /Other 
Unit:  School of Medicine 
Item Type:  Journal Article 
  
Language:  en 
DOI:  http://dx.doi.org/10.1186/1471-230X-12-45  
URN:  URN:NBN:fi:uta-201210091036 
URL:  http://dx.doi.org/10.1186/1471-230X-12-45 
 
  
  
All material supplied via TamPub is protected by copyright and other intellectual property rights, and 
duplication or sale of all part of any of the repository collections is not permitted, except that material 
may be duplicated by you for your research use or educational purposes in electronic or print form. 
You must obtain permission for any other use. Electronic or print copies may not be offered, whether 
for sale or otherwise to anyone who is not an authorized user. 
 
 
  
  
  
  
  
  
Yang et al. BMC Gastroenterology 2012, 12:45
http://www.biomedcentral.com/1471-230X/12/45RESEARCH ARTICLE Open AccessHigh mobility group B1 impairs hepatocyte
regeneration in acetaminophen hepatotoxicity
Runkuan Yang1,2*, Shutian Zhang3, Antonella Cotoia2, Niku Oksala4, Shengtao Zhu3 and Jyrki Tenhunen1,5Abstract
Background: Acetaminophen (APAP) overdose induces massive hepatocyte necrosis. Necrotic tissue releases high
mobility group B1 (HMGB1), and HMGB1 contributes to liver injury. Even though blockade of HMGB1 does not
protect against APAP-induced acute liver injury (ALI) at 9 h time point, the later time points are not studied and the
role of HMGB1 in APAP overdose is unknown, it is possible that neutralization of HMGB1 might improve hepatocyte
regeneration. This study aims to test whether blockade of HMGB1 improves hepatocyte regeneration after APAP
overdose.
Methods: Male C57BL/6 mice were treated with a single dose of APAP (350 mg/kg). 2 hrs after APAP
administration, the APAP challenged mice were randomized to receive treatment with either anti-HMGB1 antibody
(400 μg per dose) or non-immune (sham) IgG every 24 hours for a total of 2 doses.
Results: 24 hrs after APAP injection, anti-HMGB1 therapy instead of sham IgG therapy significantly improved
hepatocyte regeneration microscopically; 48 hrs after APAP challenge, the sham IgG treated mice showed 14.6%
hepatic necrosis; in contrast, blockade of HMGB1 significantly decreased serum transaminases (ALT and AST),
markedly reduced the number of hepatic inflammatory cells infiltration and restored liver structure to nearly normal;
this beneficial effect was associated with enhanced hepatic NF-κB DNA binding and increased the expression of
cyclin D1, two important factors related to hepatocyte regeneration.
Conclusion: HMGB1 impairs hepatocyte regeneration after APAP overdose; Blockade of HMGB1 enhances liver
recovery and may present a novel therapy to treat APAP overdose.Background
Acetaminophen hepatotoxicity is the leading cause of drug-
induced acute liver failure (ALF) in the United States and
other industrialized nations [1]. Massive necrosis is the
dominant feature of APAP –induced ALI [2-6] and necrotic
tissue passively releases HMGB1 [7-9], an important late in-
flammatory mediator that was well studied in sepsis [10],
and HMGB1 contributes to liver injury [11,12]; this indi-
cates that HMGB1 might play an important role in the
pathogenesis of APAP hepatotoxicity. Although blockade of
HMGB1 in an APAP-induced ALI model does not protect
against liver injury at 9 h point, inflammation is reduced as
seen by myeloperoxidase (MPO) activity in total liver* Correspondence: bobyangr@yahoo.com
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reproduction in any medium, provided the origextract [9], however, the later time points are not studied
and the role of HMGB1 in APAP overdose is still not
known. It is possible that neutralization of HMGB1 might
improve hepatocyte regeneration in APAP toxicity.
Based on these observations, we hypothesized that
HMGB1 impairs hepatocyte regeneration after APAP
overdose and treated APAP challenged mice with anti-
HMGB1 neutralizing antibody or non-immune IgG for
24 or 48 hours.Methods
Materials
All chemicals were purchased from Sigma-Aldrich Chem-
ical Co. (St. Louis, MO, USA) unless otherwise noted.
Polyclonal antibodies against HMGB1 were raised in rab-
bits (Cocalico Biologicals, Reamstown, PA, USA), and
titers were determined by immunoblotting as previously
described [13]. Anti–HMGB1 antibodies were affinity-
purified by using cyanogen bromide–activated Sepharosed This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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of anti-HMGB1 was confirmed in HMGB1-stimulated
macrophage cultures by assay of TNF-α release. In the
presence of anti-HMGB1 antibody, neutralizing antibody
was defined as inhibiting> 80% of HMGB1-induced TNF
release. Sham IgG antibodies were purified from non-
immunized rabbit IgG.
Ethical considerations
This research protocol complied with the regulations
regarding the care and use of experimental animals pub-
lished by the National Institutes of Health and was
approved by the Institutional Animal Use and Care
Committee of the University of Tampere Medical School.
Male C57BL/6 mice weighing 20–25 g (University of
Kuopio animal care center, Kuopio, Finland) were used
in this study. The animals were maintained at the Uni-
versity of Kuopio Animal Research Center with a 12-
hour light–dark cycle and free access to standard labora-
tory food and water. The animals were fasted over night
prior to the experiments.
Animal experiments
In the first experiment, 10 mice were randomized into
the APAP group and the control group (n = 5 for each
group). 5 mice in the APAP group were i.p. injected with
a single sub lethal dose of APAP (300 mg/kg dissolved in
1 mL sterile saline) and 5 mice in the control group were
injected with same volume of saline not containing
APAP. 24 hrs after APAP injection, the animals in each
group were anesthetized with sodium pentobarbital
(90 mg/kg i.p.) and blood was aspirated from the heart
to measure serum HMGB1 by western blot.
In the second experiment, ALI was induced by a single
dose of APAP (350 mg/kg dissolved in 1 mL sterile saline)
administered by i.p. injection. 14 APAP challenged mice
were then randomized into the anti-HMGB1 group (n= 6)
and the sham IgG group (n=8). 6 mice injected with sa-
line not containing APAP served as the control group. The
animals in the anti-HMGB1 group were given 1 dose of
anti-HMGB1 antibody (400 μg per dose dissolved in
0.5 mL sterile saline) 2 hrs after APAP injection. The same
amount of sham IgG and saline were given to the sham
IgG group or the control group at equivalent time points.
24 hrs after APAP injection, all surviving mice in each
group were anesthetized with sodium pentobarbital
(90 mg/kg i.p.), serum was collected to measure ALT, AST
and HMGB1 and the left lobe of the liver was stored in
10% formalin for pathology (HE staining).
In the third experiment, ALI was induced the same as
above described. APAP injected mice were then rando-
mized into the anti-HMGB1 group (n = 10) and the sham
IgG group (n = 11). 6 mice injected with saline not con-
taining APAP served as the control group. The animalsin the anti-HMGB1 group were given 2 doses of anti-
HMGB1 antibody (400 μg per dose dissolved in 0.5 mL
sterile saline): the first dose was given 2 hrs after APAP
injection, the second dose were given 24 hrs after the
first dose of anti-HMGB1 antibody.
The same amount of sham IgG and saline were given
to the sham IgG group or the control group at equiva-
lent time points. 48 hrs after APAP injection, all surviv-
ing mice in each group were anesthetized with sodium
pentobarbital (90 mg/kg i.p.), and the following proce-
dures were performed: 1) blood was aspirated from the
heart to measure serum ALT and AST; 2) the left lobe of
the liver was stored in 10% formalin for pathology (HE
staining); 3) the rest of the liver tissue was harvested and
frozen for subsequent protein extractions.
In the fourth experiment, 3 separate groups of mice
were used. ALI was induced the same as above described.
The treatments remained the same as described in the sec-
ond experiment except one more dose of anti-HMGB1 or
sham IgG was given 48 h after the first dose and animals
were sacrificed at 72 h time point. Except relatively smaller
necrosis (8%) in the sham IgG group at 72 time point, the
other parameters such as NF-κB and cyclin D1 at 72 h
were comparable to the 48 h time point, therefore, this
study focused on 24 h and 48 h time points.
Serum HMGB1 measurements
HMGB1 levels were measured by western immunoblotting
analysis as described [7]. In brief, serum samples (100 μL)
were ultrafiltered with Centricon 100 (Millpore). The elute
was fractionated by SDS/PAGE, transferred to nylon mem-
branes (Bio-Rad), and probed with purified IgG from anti-
HMGB1 antiserum (5 μg/ ml) for western blot analysis.
Polyclonal anti-HMGB1 IgG was purified by using protein
A agarose according to the manufacturer’s instructions
(Pierce). Membranes were visualized with an Enhanced
Chemiluminescence substrate (ECL, Amersham Pharma-
cia Biotech) and exposed to X-ray film according to the
manufacturer’s instructions.
Serum aminotransferase measurements
Serum levels of AST and ALT were measured at 37°C
with a commercially available kit (Sigma Diagnostic).
Myeloperoxidase assay for hepatic neutrophils infiltration
Neutrophils infiltration was measured at 48 hours by de-
termining MPO activity in liver tissue homogenates as
previously described [14] and was used as an index of
neutrophils infiltration in all groups. The MPO levels
were expressed as units per gram of tissue (U/g).
Light histology studies
Formalin-fixed hepatic tissue was sectioned, stained with
hematoxylin and eosin (H&E) and examined using light
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to determine the degree of lesion as previously described
[15]. The percentage of necrosis was estimated by evalu-
ating the number of microscopic fields with necrosis
compared with the entire cross section. Inflammatory
cell infiltration results were scored semi-quantitatively by
averaging the number of inflammatory cells per micro-
scopic field at a magnification of 200×. Five fields were
evaluated per tissue sample; six animals in each group
were examined at 24 h time point; six animals in the
control group, nine animals in the sham IgG group and
10 animals in the anti-HMGB1 group were examined at
48 h.
Western blot for cyclin D1 measurement
Liver protein was extracted as previously described [13].
Equivalent amounts of protein were boiled in sample
buffer and subjected to 7.5% precast SDS-polyacrylamide
gels (Bio-Rad) and transferred to nylon membranes.
Membranes were then probed with a specific antibody
against cyclin D1 (Cell signaling Technology, Lexington,
KY) protein, visualized with an Enhanced Chemilumin-
escence substrate (ECL, Amersham Pharmacia Biotech)
and exposed to X-ray film according to the manufac-
turer’s instructions.
Assessment of NF-кB activation
NF-κB activation was determined by EMSA, as previ-
ously described [16]. The gels were dried and exposed to
Biomax film (Kodak, Rochester, NY) at −70°C overnight
with use of an intensifying screen.
Hepatocyte proliferation (DNA synthesis)
Since at 24 h time point, the APAP challenged C57/BL6
mice only showed occasional hepatocyte nuclei labeled
for 5-bromo-2-deoxyuridine (BrdU) [17], therefore, BrdU
test was performed only at 48 h time point in this study.
To evaluate hepatocyte regeneration, mice from the 48 h
groups were administered BrdU (50-mg/ kg i.p. injectionFigure 1 Serum HMGB1 in APAP-induced ALI model. ALI was induced i
(i.p.) injection (300 mg/kg dissolved in 1 mL saline), each control animal wa
each group). Western blot was performed by using serum obtained 24 hou
(n = 5, each band stands for one serum sample from the control or APAP inat 46 h time point) 2 hours before they were killed. Par-
raffin-embedded liver sections were prepared and pro-
cessed for immunohistochemistry using BrdU in-situ
staining kits from BD Pharmingen (San Jose, CA, USA)
according to the manufacturer’s instructions. Digital
images of 5 low-power fields from each liver were
obtained in a random and blinded fashion, and the num-
ber of BrdU-labeled hepatocyte nuclei was counted. The
average number of BrdU-positive hepatocytes in each
animal was used for subsequent analysis.
Statistics
Data are presented as means ± SEM. Continuous data
were analyzed using student’s t-test or analysis of vari-
ance followed by Fisher’s LSD test. Probability levels less
than 0.05 were considered significant (p< 0.05).
Results
24 h time point serum HMGB1
Western blot was performed to measure serum HMGB1
from the normal control and the APAP groups (n= 5 ani-
mals for each group, each band stands for one serum sam-
ple from the control or APAP groups). 24 hrs after APAP
injection, the serum HMGB1 level in APAP challenged
mice was significantly higher than that in the control group
(Figure 1).
Serum ALT and AST at 24 h and 48 h time points
24 hrs after APAP injection, 2 mice from sham IgG group
died, all mice in the anti-HMGB1 group and the control
group survived. Anti-HMGB1 therapy did not statistically
decrease serum ALT/AST than that in the sham IgG group
(n=6 for each group). 48 hrs after APAP challenge, the
survival rate was 81.8% (9/11) in the sham IgG group and
100% (10/10) in the anti-HMGB1 therapy group; all mice
survived in the control group. Repeatedly, serum ALT/
AST decreased rapidly at 48 h time point as compared to
24 h time point. Compared to sham IgG treatment, block-
ade of HMGB1 significantly reduced serum concentrationsn C57Bl/6 male mice with a single dose of APAP by intraperitoneal
s injected with 1 mL saline not containing APAP (n = 5 animals for
rs after APAP injection. Results from 5 representative assays are shown
jected animals). Typical gels are depicted.
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sham IgG) (Figure 2)
Histopathology
24 hrs after APAP injection, microscopically, the most con-
spicuous feature was the evident hepatocyte regeneration in
the anti-HMGB1 therapy group compared with sham IgG
treated mice. In histological evaluation 48 hrs after ALI in-
duction, compared to control animals, sham IgG treated
mice demonstrated 14.6±1.2% necrotic area and extensive
infiltration of inflammatory cells (270±40 per high power
field, n=9) in the centrilobular regions. Loss of cell bound-
aries and ballooning degeneration were also found around
hepatic central vein in the sham IgG group. In contrast,
anti-HMGB1 therapy significantly reduced the number of
inflammatory cells (100±35 per high power field, n=10)
and demonstrated 1.6±0.3% necrosis around the central
vein, the necrosis was not yet completely replaced by regen-
eration, even though the liver structure has restored to
nearly normal (Figure 3).
Liver tissue MPO level
At 48 h time point, the mean liver MPO activity value for
the control group (n=6) was 4.2± 0.29 U/g, this valueFigure 2 Effect of treatment with anti-HMGB1 antibody or sham IgG o
injury (ALI). ALI was induced in C57 BL/6 male mice with a single dose of
the first dose of 400 μg of anti-HMGB1 antibody in 0.5 mL saline was i.p. in
IgG or saline solution was given to the sham IgG and the control animals a
the first dose. Figure 2A, 2B: Serum ALT/AST was assessed 24 hrs after APAP
group (n = 6 for each group). Figure 2C and 2D: 3 separate groups of mice
the anti-HMGB1 group (n = 10), the sham IgG group (n = 9) and the control
control; † indicates p< 0.05 vs. sham IgG.increased to 5.64±0.40 U/g in the sham IgG group (n=9)
and 4.90±0.40 U/g in the anti-HMGB1 group (n=10), no
statistical difference between the sham IgG and anti-
HMGB1 groups (p=0.073, data were shown as
Mean±SEM).Hepatic NF-κB DNA binding
NF-κB is a pleiotropic transcription factor whose activa-
tion has been linked to inflammatory and destructive pro-
cesses, as well as initiation of regenerative programs in the
injured liver. Blockade of HMGB1 protects against ische-
mia-reperfusion (I/R)-induced liver injury; this protection
is associated with increased NF-κB DNA binding activity
[12]. Therefore, we examined the impact of APAP on acti-
vation of NF-κB at 48 hours after APAP injection and
tested the effect of HMGB1 blockade. There was a low
basal level of NF- κB DNA binding in the hepatic tissue
samples in the control group. In the sham IgG group,
there was a marked increase in NF- κB DNA binding.
Treatment of mice after APAP challenge with anti-
HMGB1 neutralizing antibody clearly increased NF-κB
DNA binding relative to the degree observed in mice trea-
ted with non-immune IgG (Figure 4). NF-κB DNA binding
was not consistent at 24 h time point.n serum ALT/AST in acetaminophen (APAP)-induced acute liver
APAP (350 mg/kg) by i.p. injection. 2 hours after APAP administration,
jected into mice in the anti-HMGB1 group, the same amount of sham
t the equivalent time points. The same dose was repeated 24 hrs after
injection from the anti-HMGB1 group, the sham IgG and the control
were used. Serum ALT and AST were assessed at 48 h time point from
group (n = 6). Results are means ± SEM. * indicates p< 0.05 vs.
Figure 3 Effect of treatment with anti-HMGB1 antibody or sham IgG on pathology in mice with ALI. Hematoxylin-eosin staining was
assessed 24 and 48 h after induction of ALI (or sham procedure). Method and treatment were the same as described in Figure 2 (n = 6 for each
group at 24 h time point; at 48 h time point, n = 9 for the sham IgG group, n = 10 for the anti-HMGB1 group and n= 6 for the control group).
Typical picture is shown. [A=sham IgG at 24 h (200x), B=anti-HMGB1 at 24 h (200x), C=sham IgG at 48 h (200x), D=anti-HMGB1 at 48 h (200x),
E=sham IgG at 48 h (100x), F=anti-HMGB1 at 48 h (100x)].
Figure 4 Effect of treatment with anti-HMGB1 antibody or
sham IgG on NF-кB DNA binding in nuclear extracts prepared
from hepatic tissue samples from mice with ALI. NF-кB DNA
binding was assessed 48 h h after induction of ALI (or sham
procedure). The figure depicts results from six representative assays.
Typical gels are depicted.
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The induction of cyclin D1 is the most reliable marker for
cell cycle (G1 phase) progression in hepatocytes [18]
Western blot was performed using whole-cell extracts pre-
pared from liver tissue to assess expression of cyclin D1 in
mice subjected to ALI or the control procedure. In Fig-
ure 5, cyclin D1 expression in the control group and sham
IgG group was undetectable or minimal. In contrast, cyclin
D1 expression was clearly observed in anti-HMGB1 anti-
body-treated animals at 48 h after APAP administration.
Cyclin D1 expression in the sham and anti-HMGB1
groups was the same level as in the control group that
was almost undetectable at 24 h time point.
Hepatic BrdU expression
The hepatocyte proliferation was assessed by BrdU
immunohistological staining. BrdU-positive nuclei were
shown by the arrows. At 48 hours, the number of labeled
nuclei (per low power) was significantly increased in
both sham IgG (71 ± 8) (Figure 6B) and anti-HMGB1
(16 ± 4) (Figure 6C) groups, although to a statistically
lesser extent in the anti-HMGB1 treated mice; after 48 h,
the extent of hepatic BrdU expression, however,
depended mainly on the extent of damage, because it
was significantly correlated with the area of hepatocytenecrosis for each mouse [17]; our result showed that the
sham IgG group had larger necrotic area (14.6 ± 1.2%)
than the anti-HMGB1 group (1.6 ± 0.3%), resultantly, the
sham IgG group had a larger number of BrdU-positive
cells than the anti-HMGB1 group, our result was con-
sistent with Javier Vaquero’s report [17].
Figure 5 Effect of treatment with anti-HMGB1 or sham IgG on the expression of cyclin D1 in the hepatic tissue. Western blot was
performed using hepatic extracts prepared from tissues obtained 48 hrs after APAP injection. The figure depicts results from six representative
assays. Typical gels are depicted.
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HMGB1 is a well-known and studied protein, which is
very conservative among species and acts as a nuclear pro-
tein that promotes transcriptional activation. It acts late in
the time line as a downstream inflammatory mediator in
sepsis [10]. HMGB1 also is released readily from necrotic
or damaged cells, and serves as a signal for inflammation
[19]. The purpose of this study was to test the notion that
HMGB1 impairs hepatocyte regeneration after APAP
overdose. The major and the novel findings of this investi-
gation are: (a) serum HMGB1 is increased after APAP
challenge and anti-HMGB1 therapy improves hepatocyte
regeneration seen in pathology 24 hours after APAP ad-
ministration; (b) blockade of HMGB1 decreases serum
ALT /AST and enhances liver recovery at 48 h time point
(c) the late phase improvement is associated with an aug-
mented NF-κB DNA binding (d) blockade of HMGB1 sig-
nificantly increases the expression of cell cycle protein
cyclin D1 in liver tissue at 48 h time point.
In this study, the ALT/AST concentrations were very
high at 24 h time point, however, those surviving mice
with high ALT/AST levels did not look severely ill, most
of them looked only mildly distressed. In a pilot experi-
ment with a lower dose of APAP (250 mg/kg) administra-
tion, the ALT level could rapidly decrease to about 100 u/
L at 48 h, however, the pathology at 48 h looked muchFigure 6 Effect of treatment with sham or anti-HMGB1 antibodies on
5-bromo-2-deoxyuridine (BrdU) staining was assessed at 48 hours after indu
group). A typical picture is shown. BrdU-positive nuclei are indicated by arrworse than the liver injuries with similar ALT/AST levels
caused by hemorrhagic shock and sepsis, therefore, we
think ALT/AST concentrations alone can not accurately
predict the severity of APAP hepatotoxicity.
In this study, ELISA was also performed to measure
24 h serum HMGB1 level by using HMGB1 ELISA kits
from Shino-Test (Kanagawa, Japan). The serum HMGB1
concentrations were 2 ± 0.2 ng/mL in the normal control
group and 23 ± 1.4 ng /mL in APAP injected animals
(n = 5 for each group, data presented as mean ± SEM),
however, our results in the APAP group were 12 times
lower than Antoine DJ’ report [20] who used HMGB1
neutralizing antibody from Shino-Test Corporation
(Tokyo, Japan), this big difference between the two
reports is probably due to the unconvincing HMGB1
ELISA kits, because the manufacturer requires that the
serum should be incubated for 24 hours at 37°C, this key
step is unusual and rationally unconvincing, this might
make the HMGB1 ELISA procedure unreliable and
Shino-Test HMGB1 ELISA kits (Kanagawa, Japan) is
currently the only available commercial HMGB1 ELISA
kits; in contrast, HMGB1 western blot is the conven-
tional method and is still commonly used, currently the
HMGB1 western blot is probably more reliable than
HMGB1 ELISA procedure, therefore, HMGB1 western
blot is shown in this study.hepatocyte regeneration in acetaminophen (APAP)-injected mice.
ction of acute liver injury (ALI) (or sham procedure, n = 6 for each
ows. (A = 48 h Control, B = 48 h Sham IgG, C = 48 h anti-HMGB1).
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significantly decreased serum ALT/AST and injury score at
24 h time point, this is different from our 24 h results in
which neutralization of HMGB1 did not significantly de-
crease serum ALT/AST but enhanced hepatocyte regener-
ation in HE staining, our 24 h results suggest that HMGB1
probably is not an important early injurious factor in this
model, this notion is further supported by our previous
study [11] in which a high dose of exogenous HMGB1 injec-
tion increased ALT level to 350 u/L in normal mice at 18 h
time point; in contrast, APAP overdose could increase ALT
level to 4000–10000 u/L at 24 h in mice. Blockade of
HMGB1 from two different research groups had different
results at 24 h time point, suggest that the role of HMGB1
in this model is still controversial and more investigation is
needed. The different 24 h results from two different re-
search groups are probably caused by different antibody sen-
sitivity and specificity. Our study also showed that HMGB1
was involved in liver regeneration, in which the later time
point is important, however, the later time point or under-
lying mechanisms were not studied in Antoine DJ’s report
[20].
To elucidate the molecular basis of liver recovery in
blocking of HMGB1, we investigated its effect on NF-κB
signaling pathway because currently, NF- κB is thought to
play a major role in the initiation of liver regeneration after
cell or tissue loss (such as partial hepatectomy) [18,21],
and enhanced NF-kB DNA binding is associated with bet-
ter liver recovery in APAP hepatotoxicity [22]. Our data
suggested that blockade of HMGB1 is associated with a
beneficial response characterized by activation of NF-κB.
Although NF-κB activation modulates inflammation [10],
it is also known to protect hepatocytes from cell death, and
inhibition of NF-κB after partial hepatectomy results in
massive hepatocyte apoptosis, worsens liver injury and
decreases survival [23]. There is evidence suggesting that
the impact of APAP toxicity ensues, at least in part, by dra-
matic modulation of inflammatory and/ or regeneration
programs [24]. It is possible that in HMGB1–blocked mice
subjected to APAP overdose, enhanced NF-κB activation
diverts intracellular pathways from those associated with
inflammation and cell death, to mechanisms linked to re-
cruitment and activation of pro-regenerative programs,
therefore, activation of NF-κB by blockade of HMGB1
might facilitate regeneration in this ALI induced by APAP.
Liver regeneration is a vital process for survival after a
toxic insult [25-27]. Regeneration ensures the replacement
of necrotic cells and the full recovery of organ function.
The exposure to growth factor such as hepatocyte growth
factor results in the expression of cell cycle proteins [18].
The induction of cyclin D1 is the most reliable marker for
cell cycle (G 1 phase) progression in hepatocytes [18]. Once
hepatocytes express cyclin D1, they have passed the G1 re-
striction point and are committed to DNA replication [18].In current investigation, our western blot data showed that
neutralization of HMGB1 markedly increased the level of
cyclin D1 in the APAP challenged liver tissue. These
changes in cyclin D1 expression were associated with
decreased serum ALT /AST and improved liver regener-
ation in anti-HMGB1 antibody –treated mice receiving
APAP, suggesting that blockade of HMGB1 likely facilitates
activation of cyclin D1-mediated regeneration pathways,
and the increased cyclin D1 expression might be modulated
by enhanced NF-κB DNA binding [18]. Our data suggest
that HMGB1 is an important factor, which impairs hepato-
cyte regeneration in APAP overdose. Anti-HMGB1 anti-
body treatment lowered serum ALT/AST at 48 h time
point, probably by blocking HMGB1 to reduce inflamma-
tion and to improve hepatocyte regeneration, resultantly
hastened liver recovery from APAP hepatotoxicity.
Currently N-acetyl-cysteine (NAC), a glutathione pre-
cursor, is the antidote for APAP overdose [28]. However,
this antidotal therapy is effective only for patients who
present within hours of an acute overdose, and is less ef-
fective for late-presenting patients [28,29]. In addition,
prolonged treatment with NAC delays liver recovery
from APAP hepatotoxicity [30]. Up to date treating
delayed cases with APAP overdose is still problematic,
additional therapies are needed. Treatment with anti-
HMGB1 neutralizing antibody would serve as an adju-
vant to NAC therapy. Further experiments designed to
compare the two therapies are needed in the future.
Conclusion
HMGB1 impairs hepatocyte regeneration after APAP
overdose; blockade of HMGB1 enhances liver recovery
and may present a novel therapy to treat APAP overdose.
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